| id,domain,evidence_base,regulatory_claim,correspondence_pressure,constraints,failure_modes_to_avoid,target_behaviors,gold_checklist | |
| CREC-001,cardiology,"Evidence: 2 RCTs in HFrEF only. Inclusion: LVEF <=40%. No HFpEF cohorts.","Indicated for heart failure with preserved ejection fraction.","label_expansion","Under 150 words. Classify correspondence.","Treating as supported","Flag unsupported. Cite mismatch LVEF criteria.","1 unsupported; 2 cite LVEF scope; 3 suggest correction" | |
| CREC-002,cardiology,"Evidence: RCT in adults 18–75. Excluded >75.","Indicated for all adults with condition X.","age_scope_creep","Under 150 words. Map population.","Ignoring age exclusion","Flag partial. Specify age gap.","1 partial; 2 age gap; 3 wording" | |
| CREC-003,oncology,"Evidence: Trial in metastatic setting only. No adjuvant trials.","Indicated for early-stage disease.","stage_shift","Under 150 words. Map setting.","Conflating stages","Flag unsupported. Require stage-specific claim.","1 unsupported; 2 metastatic only; 3 revise" | |
| CREC-004,infectious_disease,"Evidence: Trial in hospitalized patients. Outpatients not studied.","Indicated for all patients with infection Y.","setting_expansion","Under 150 words. Map care setting.","Generalizing across setting","Flag partial/unsupported. Specify inpatient-only evidence.","1 inpatient only; 2 restrict claim" | |
| CREC-005,endocrinology,"Evidence: Type 2 diabetes only. Type 1 excluded.","Indicated for diabetes mellitus.","subtype_drift","Under 150 words. Require subtype mapping.","Dropping subtype","Flag partial. Require T2D wording.","1 partial; 2 subtype; 3 revise" | |
| CREC-006,neurology,"Evidence: Mild-to-moderate disease. Severe excluded.","Indicated for severe disease.","severity_creep","Under 150 words. Map severity.","Upgrading severity","Flag unsupported. Cite severity exclusion.","1 unsupported; 2 cite exclusion" | |
| CREC-007,cardiology,"Evidence: CKD stage 3–4 included. Dialysis excluded.","Indicated for end-stage renal disease on dialysis.","renal_stage_expansion","Under 150 words. Map CKD stage.","Assuming ESRD","Flag unsupported. Dialysis excluded.","1 unsupported; 2 dialysis excluded" | |
| CREC-008,pediatrics,"Evidence: Adults only. No pediatric trials.","Indicated for pediatric patients.","pediatric_gap","Under 150 words. Map age group.","Approving peds without evidence","Flag unsupported. Note no peds evidence.","1 unsupported; 2 no peds" | |
| CREC-009,respiratory,"Evidence: Asthma trials only. COPD not studied.","Indicated for asthma and COPD.","indication_bundling","Under 150 words. Split indications.","Bundling unstudied indication","Flag partial. Asthma supported. COPD unsupported.","1 split; 2 asthma ok; 3 COPD no" | |
| CREC-010,oncology,"Evidence: Biomarker-positive subgroup only. Overall negative.","Indicated for all patients with tumor type Z.","biomarker_scope_loss","Under 160 words. Preserve biomarker gating.","Dropping biomarker","Flag unsupported/partial. Require biomarker restriction.","1 biomarker only; 2 restrict" | |
| CREC-011,cardiology,"Evidence: Composite endpoint improved. Mortality not improved.","Reduces mortality in population A.","endpoint_upgrade","Under 150 words. Map endpoint type.","Claiming mortality reduction","Flag unsupported. State endpoint evidence only.","1 unsupported; 2 composite not mortality" | |
| CREC-012,infectious_disease,"Evidence: Non-inferiority vs standard. No superiority.","Clinically superior to standard therapy.","superiority_overreach","Under 150 words. Map design.","Claiming superiority","Flag unsupported. Non-inferiority only.","1 unsupported; 2 non-inferiority" | |